

Serial No.: 09/807,657  
Group Art Unit No.: 1648

**In the Claims:**

Claims 1-31 (Cancelled).

32. (Previously Presented) An adjuvant composition comprising an immunostimulant adsorbed onto a metallic salt particle, wherein the metallic salt particle is substantially free of antigen and wherein the immunostimulant is not a saponin derived from the bark of Quillaja Saponaria Molina.

33. (Previously Presented) An adjuvant composition as claimed in claim 32, wherein the metallic salt particle is a salt of aluminium, zinc, calcium, cerium, chromium, iron, or berilium.

34. (Previously Presented) An adjuvant composition as claimed in claim 32, wherein the metallic salt is a phosphate or hydroxide.

35. (Previously Presented) An adjuvant composition as claimed in claim 32, wherein the metallic salt is aluminium hydroxide or aluminium phosphate.

36. (Previously Presented) An adjuvant composition as claimed in claim 32, wherein the immunostimulant is monophosphoryl lipid A or a derivative thereof.

37. (Previously Presented) An adjuvant composition as claimed in claim 36, wherein the derivative of monophosphoryl lipid A is 3-de-O-acylated monophosphoryl lipid A.

38. (Cancelled).

39. (Currently Amended) A process for the manufacture of a vaccine composition comprising the admixture of a) an adjuvant composition comprising an immunostimulant adsorbed onto a first metallic salt particle substantially free of antigen, and b) an antigen.

40. (Currently Amended) A process for the manufacture of a vaccine composition as claimed in claim 39, wherein the antigen is adsorbed onto a second metallic salt particle substantially free

Serial No.: 09/807,657  
Group Art Unit No.: 1648

of antigen wherein the metallic salt of each of the first metallic salt particle and the second metallic salt particle may be the same.

41. (Currently Amended) A process as claimed in claims 39, wherein the antigen ~~is-elicits an~~ immune response to a pathogen, polypeptide, or anti-tumour antigen selected from the group comprising: antigens derived from Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex Virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, human papilloma virus, Influenza virus, Haemophilus influenzae Type B ("Hib"), Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, IgE peptides, Der p1, pollen related antigens; or Tumor associated antigens (TAA), MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, KSA, ~~or~~ and PRAME.

42. (Previously Presented) A vaccine composition comprising an adjuvant composition according to any one of claims 32 to 37, additionally comprising an antigen.

43. (Currently Amended) A vaccine composition produced according to the process claimed in any one of claims 39 to 41.

44. (Previously Presented) A vaccine comprising a saponin adsorbed onto a metallic salt particle wherein the vaccine comprises an antigen, characterised in that the metallic salt particle is substantially free of said antigen.

45. (Previously Presented) A vaccine according to claim 44, wherein the saponin is QS21.

46. (Previously Presented) A vaccine composition comprising two major populations of complexes, a first complex comprising (a) an immunostimulant adsorbed onto a metallic salt particle, characterised in that said metallic salt particle is substantially free of antigen; and a second complex comprising (b) antigen adsorbed onto a metallic salt particle.

Serial No.: 09/807,657  
Group Art Unit No.: 1648

47. (Previously Presented) A vaccine composition comprising two major populations of complexes, a first complex comprising (a) an immunostimulant adsorbed onto a metallic salt particle, characterised in that said metallic salt particle is substantially free of antigen; and a second complex comprising (b) antigen adsorbed onto a metallic salt particle, characterised in that said metallic salt particle is substantially free of immunostimulant of the first complex.
48. (Previously Presented) A vaccine composition as claimed in claims 46 or 47, wherein the metallic salt present in the first and second complexes are identical.
49. (Previously Presented) A vaccine composition as claimed in claims 46 or 47, wherein the second complex comprises a plurality of sub-complexes, each sub-complex comprising a different antigen adsorbed onto a metallic salt particle.
50. (Previously Presented) A vaccine composition as claimed in any one of claims 44 to 47, wherein the metallic salt is a salt of aluminium, zinc, calcium, cerium, chromium, iron, or berilium.
51. (Previously Presented) A vaccine as claimed in claim 50 wherein the metallic salt is a phosphate or hydroxide.
52. (Previously Presented) A vaccine composition as claimed in claim 51 wherein the metallic salt is aluminium hydroxide or aluminium phosphate.
53. (Previously Presented) A vaccine composition as claimed in claim 42, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.
54. (Previously Presented) A vaccine composition as claimed in claim 43, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.
55. (Previously Presented) A vaccine composition as claimed in claim 45, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.
56. (Previously Presented) A vaccine composition as claimed in claim 46, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

Serial No.: 09/807,657  
Group Art Unit No.: 1648

57. (Previously Presented) A vaccine composition as claimed in claim 47, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

58. (Previously Presented) A vaccine composition as claimed in claim 48, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

59. (Previously Presented) A vaccine composition as claimed in claim 49, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

60. (Previously Presented) A vaccine composition as claimed in claim 50, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

61. (Previously Presented) A vaccine composition as claimed in claim 51, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

62. (Previously Presented) A vaccine composition as claimed in claim 52, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

Claims 63-70. (Cancelled).

71. (Currently Amended) A vaccine composition as claimed in claim 42, wherein the antigen is elicits an immune response against a pathogen, polypeptide, or anti-tumour antigen selected from the group ~~comprising~~ consisting of: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, *Haemophilus influenzae* Type B ("Hib"), Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, ~~or~~ and PRAME.

72. (Currently Amended) A vaccine composition as claimed in claim 43, wherein the antigen is elicits an immune response against a pathogen, polypeptide, or anti-tumour antigen selected from the group ~~comprising~~ consisting of: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus,

Serial No.: 09/807,657  
Group Art Unit No.: 1648

Influenza virus, *Haemophilus influenzae* Type B ("Hib"), Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, ~~or~~and PRAME.

73. (Currently Amended) A vaccine composition as claimed in claim 44, wherein the antigen is elicits an immune response against a pathogen, polypeptide, or anti-tumour antigen selected from the group ~~comprising~~ consisting of: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, *Haemophilus influenzae* Type B ("Hib"), Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, ~~or~~and PRAME.

74. (Currently Amended) A vaccine composition as claimed in claim 45, wherein the antigen is elicits an immune response against a pathogen, polypeptide, or anti-tumour antigen selected from the group ~~comprising~~ consisting of: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, *Haemophilus influenzae* Type B ("Hib"), Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, ~~or~~and PRAME.

75. (Currently Amended) A vaccine composition as claimed in claim 46, wherein the antigen is elicits an immune response against a pathogen, polypeptide, or anti-tumour antigen selected from the group ~~comprising~~ consisting of: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, *Haemophilus influenzae* Type B ("Hib"), Meningitis virus, Salmonella,

Serial No.: 09/807,657  
Group Art Unit No.: 1648

Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, ~~or~~and PRAME.

76. (Currently Amended) A vaccine composition as claimed in claim 47, wherein the antigen is elicits an immune response against a pathogen, polypeptide, or anti-tumour antigen selected from the group ~~comprising~~ consisting of: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, *Haemophilus influenzae* Type B ("Hib"), Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, ~~or~~and PRAME.

77. (Currently Amended) A vaccine composition as claimed in claim 48, wherein the antigen is elicits an immune response against a pathogen, polypeptide, or anti-tumour antigen selected from the group ~~comprising~~ consisting of: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, *Haemophilus influenzae* Type B ("Hib"), Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, ~~or~~and PRAME.

78. (Currently Amended) A vaccine composition as claimed in claim 49, wherein the antigen is elicits an immune response against a pathogen, polypeptide, or anti-tumour antigen selected from the group ~~comprising~~ consisting of: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, *Haemophilus influenzae* Type B ("Hib"), Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide,

Serial No.: 09/807,657  
Group Art Unit No.: 1648

Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, ~~or~~ and PRAME.

79. (Currently Amended) A vaccine composition as claimed in claim 50, wherein the antigen is elicits an immune response against a pathogen, polypeptide, or anti-tumour antigen selected from the group ~~comprising~~ consisting of: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, *Haemophilus influenzae* Type B ("Hib"), Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, ~~or~~ and PRAME.

80. (Currently Amended) A vaccine composition as claimed in claim 51, wherein the antigen is elicits an immune response against a pathogen, polypeptide, or anti-tumour antigen selected from the group ~~comprising~~ consisting of: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, *Haemophilus influenzae* Type B ("Hib"), Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, ~~or~~ and PRAME.

81. (Currently Amended) A vaccine composition as claimed in claim 52, wherein the antigen is elicits an immune response against a pathogen, polypeptide, or anti-tumour antigen selected from the group ~~comprising~~ consisting of: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, *Haemophilus influenzae* Type B ("Hib"), Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide,

Serial No.: 09/807,657  
Group Art Unit No.: 1648

Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, ~~or~~ and PRAME.

82. (Previously Presented) A vaccine composition as claimed in claim 71, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

83. (Previously Presented) A vaccine composition as claimed in claim 72, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

84. ((Previously Presented) A vaccine composition as claimed in claim 73, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

85. (Previously Presented) A vaccine composition as claimed in claim 74, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

86. (Previously Presented) A vaccine composition as claimed in claim 75, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

87. (Previously Presented) A vaccine composition as claimed in claim 76, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

88. (Previously Presented) A vaccine composition as claimed in claim 77, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

89. (Previously Presented) A vaccine composition as claimed in claim 78, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

90. (Previously Presented) A vaccine composition as claimed in claim 79, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.



Serial No.: 09/807,657  
Group Art Unit No.: 1648

91. (Previously Presented) A vaccine composition as claimed in claim 80, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.
92. (Previously Presented) A vaccine composition as claimed in claim 81, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.
93. (Previously Presented) A vaccine composition as claimed in claim 71, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.
94. (Previously Presented) A vaccine composition as claimed in claim 72, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.
95. (Previously Presented) A vaccine composition as claimed in claim 73, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.
96. (Previously Presented) A vaccine composition as claimed in claim 74, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.
97. (Previously Presented) A vaccine composition as claimed in claim 75, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.
98. (Previously Presented) A vaccine composition as claimed in claim 76, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.
99. (Previously Presented) A vaccine composition as claimed in claim 77, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.

Serial No.: 09/807,657  
Group Art Unit No.: 1648

100. (Previously Presented) A vaccine composition as claimed in claim 78, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.

101. (Previously Presented) A vaccine composition as claimed in claim 79, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.

102. (Previously Presented) A vaccine composition as claimed in claim 80, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.

103. (Previously Presented) A vaccine composition as claimed in claim 81, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.

104. (Previously Presented) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 71.

105. (Previously Presented) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 72.

106. (Previously Presented) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 73.

107. (Previously Presented) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 74.

108. (Previously Presented) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 75.

Serial No.: 09/807,657  
Group Art Unit No.: 1648

109. (Previously Presented) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 76.
110. (Previously Presented) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 77.
111. (Previously Presented) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 78.
112. (Previously Presented) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 79.
113. (Previously Presented) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 80.
114. (Previously Presented) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 81.
115. (Previously Presented) A kit comprising two containers, one container having monophosphoryl lipid A, or derivative thereof, adsorbed onto a metallic salt; and the second container having antigen adsorbed onto a metallic salt.
116. (Previously Presented) An vaccine composition comprising: a) an immunostimulant adsorbed onto a metallic salt particle, wherein the immunostimulant is selected from the group consisting of bacterially derived compounds, monophosphoryl lipid A, immunostimulatory oligonucleotides, CpG, block copolymers, cholera toxin, immunostimulatory cytokines, GM-CSF, IL-1, polyriboA, polyriboU, and Muramyl tripeptide, and b) an antigen, wherein the antigen is not adsorbed onto the metallic salt particle.

Serial No.: 09/807,657  
Group Art Unit No.: 1648

117. (Cancelled).

118. (Previously Presented) An adjuvant composition comprising an immunostimulant adsorbed onto a metallic salt particle, wherein the metallic salt particle is substantially free of antigen and in that the immunostimulant is not a saponin derived from the bark of Quillaja Saponaria Molina.

119. (Currently Amended) A process for the manufacture of a vaccine composition comprising the admixture of a) an adjuvant composition comprising an immunostimulant adsorbed onto a metallic salt particle substantially free of antigen, and b) an antigen.

120. (New) A process as claimed in claim 41, wherein the antigen elicits an immune response to human papilloma virus (HPV).

121. (New) The process according to claim 120, wherein the HPV is selected from the group of: HPV 6, 11, 16 and 18.

122. (New) The process according to claim 120, wherein the antigen is an L1 particle or capsomer.

123. (New) A vaccine composition accordingly to claim 42 wherein the antigen elicits an immune response to human papilloma virus (HPV).

124. (New) The vaccine composition according to claim 123, wherein the HPV is selected from the group of: HPV 6, 11, 16 and 18.

125. (New) A vaccine composition according to claim 123, wherein the antigen is an L1 particle or capsomer.